Business
Medicenna Presents Clinical Validation of the IL4 Receptor as a Biomarker for MDNA55 in Recurrent Glioblastoma
Medicenna Presents Clinical Validation of the IL4 Receptor as a Biomarker for MDNA55 in Re...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presents Clinical Validation of the IL4 Receptor as a Biomarker for MDNA55 in Recurrent Glioblastoma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, June 3, 2019\n\n\n\n75% of IL4R+ve Patients Achieve Disease Control Following One Treatment With MDNA55\n TORONTO and HOUSTON, TX, June 3, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, presented a poster entitled \"MDNA55: A Locally Administered IL4 Guided Toxin as a Targeted Treatment for Recurrent Glioblastoma\" at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, IL.\nThe presentation by Dr. Dina Randazzo of Duke University School of Medicine and a Principal Investigator in the Phase 2b clinical trial MDNA55-05, which recently completed its enrollment (N=46), focused on the development of a new biomarker test for the interleukin-4 receptor (IL4R) that may enable better selection and superior treatment outcomes for patients with recurrent glioblastoma (\"rGBM\"), a highly aggressive and uniformly fatal form of brain cancer.\nHighlights from the presentation, encompassing 18 of 21 subjects enrolled in the low dose cohort of the trial and with IL4R results, are summarized below:\n75% (6 of 8) of subjects with moderate to high IL4R (IL4R+ve) expression show disease control (tumor shrinkage or tumor stabilization from baseline) without clinical decline on assessment of imaging data within 90 days following a single treatment with MDNA55. This is compared to 25% (2 of 8) in subjects with no/low IL4R (IL4R-ve ) expression. Sixteen of 18 subjects were evaluable for tumor response. 100% (8 of 8) of IL4R+ve subjects show disease control compared to 38% (3 of 8) of IL4R-ve subjects, following initial pseudoprogression in some subjects. IL4R expression appears to be predictive of a more aggressive form of GBM. Patients with IL4R+v...